발생일자 2015.07.17 

사건번호 1:15-cv-00617 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.Delaware(지방법원) 

침해권리 특허 

원고명 Meda Pharmaceuticals, Inc. ( 미국 / 외국기업 )  

피고명 Amneal Pharmaceuticals, LLC/ Amneal Pharmaceuticals Co. India Private Limited/ Amneal Pharmaceuticals of New York, LLC ( 미국 / 외국기업 )  

소송유형 침해금지 

[Meda Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC et al] 사건번호 1:15-cv-00617에 따르면 원고 Meda Pharmaceuticals, Inc.는 피고 Amneal Pharmaceuticals, LLC/ Amneal Pharmaceuticals Co. India Private Limited/ Amneal Pharmaceuticals of New York, LLC을(를) 상대로 특허 US8071073|US8518919을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Azelastine hydrochloride nasal spray, 0.15%, 205.5 mcg per spray, generic version of ASTEPRO 

지재권번호/명칭

US8071073   Compositions comprising azelastine and methods of use thereof 

US8518919   Compositions comprising azelastine and methods of use thereof 

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance. 

 1. A liquid pharmaceutical composition for treating allergic rhinitis or non-allergic vasomotor rhinitis, said liquid pharmaceutical composition comprising: about 0.100% (w/v) azelastine hydrochloride; about 0.100% (w/v) of hypromellose; about 0.05% (w/v) disodium edetate; about 0.025% (w/v) benzalkonium chloride 50% solution, NF; about 0.150% (w/v) sucralose; about 6.4% (w/v) sorbitol 70%; about 0.068% (w/v) sodium citrate dihydrate; and QS water, wherein said liquid pharmaceutical composition is formulated in the form of a nasal spray or nasal drops. 

 2. A liquid pharmaceutical composition for treating allergic rhinitis or non-allergic vasomotor rhinitis, said liquid pharmaceutical composition comprising: about 0.1% to about 0.15% (w/v) azelastine hydrochloride; about 0.1% to about 0.15% (w/v) sucratose; and about 0.1% to about 10% (w/v) sorbitol 70%, wherein said liquid pharmaceutical composition is formulated in the form of a nasal spray or nasal, drops. 

 3. A liquid pharmaceutical composition for treating allergic rhinitis or non-allergic vasomotor rhinitis, said liquid pharmaceutical composition comprising: about 0.150% (w/v) azelastine hydrochloride; about 0.100% (w/v) of hypromellose; about 0.05% (w/v) disodium edetate; about 0.001% to about 0.5% (w/v) benzalkonium chloride 50% solution, NF; about 0.150% (w/v) sucralose; about 0.1% to about 10% (w/v) sorbitol 70%; about 0.068% (w/v) sodium citrate dihydrate; and QS water, wherein said liquid pharmaceutical composition is formulated in the form of a nasal spray or nasal drops. 

 4. The liquid pharmaceutical composition of claim 1, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 

 5. The liquid pharmaceutical composition of claim 4, wherein said intranasal delivery system comprises a bottle and a pump. 

 6. The liquid pharmaceutical composition of claim 5, wherein said pump is a metered multi-dose pump. 

 7. The liquid pharmaceutical composition of claim 2, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 

 8. The liquid pharmaceutical composition of claim 7, wherein said intranasal delivery system comprises a bottle and a pump. 

 9. The liquid pharmaceutical composition of claim 8, wherein said pump is a metered multi-dose pump. 

 10. The liquid pharmaceutical composition of claim 3, wherein said liquid pharmaceutical composition is contained within an intranasal delivery system. 

 11. The liquid pharmaceutical composition of claim 10, wherein said intranasal delivery system comprises a bottle and a pump. 

 12. The liquid pharmaceutical composition of claim 11, wherein said pump is a metered multi-dose pump. 

 13. The liquid pharmaceutical composition of claim 1, wherein said liquid pharmaceutical composition is in the form of a nasal spray. 

 14. The liquid pharmaceutical composition of claim 2, wherein said liquid pharmaceutical composition is in the form of a nasal spray. 

 15. The liquid pharmaceutical composition of claim 3, wherein said liquid pharmaceutical composition is in the form of a nasal spray. 

 16. The liquid pharmaceutical composition of claim 13, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 ml to about 0.15 ml per spray. 

 17. The liquid pharmaceutical composition of claim 13, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray. 

 18. The liquid pharmaceutical composition of claim 14, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 ml to about 0.15 ml per spray. 

 19. The liquid pharmaceutical composition of claim 14, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray. 

 20. The liquid pharmaceutical composition of claim 15, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 ml to about 0.15 m1 per spray. 

 21. The liquid pharmaceutical composition of claim 15, wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray. 

 22. The liquid pharmaceutical composition of claim 2, wherein said liquid pharmaceutical composition further comprises: hypromellose; disodium edetate; benzalkonium chloride 50% solution, NF; sodium citrate dihydrate; and QS water. 

 23. The liquid pharmaceutical composition of claim 2, wherein said liquid pharmaceutical composition further comprises: about 0.001% to about 5.00% (w/v) of hypromellose; about 0.01% to about 0.1% (w/v) disodium edetate; about 0.001% to about 0.5% (w/v) benzalkonium chloride 50% solution, NF; about 0.068% (w/v) sodium citrate dihydrate; and QS water. 

 24. The liquid pharmaceutical composition of claim 2, wherein the concentration of sorbitol in said liquid pharmaceutical composition is sufficient for the osmolality of said liquid pharmaceutical composition to be from about 220 mOsmol/kg to about 350 mOsmol/kg. 

 25. The liquid pharmaceutical composition of claim 3, wherein the concentration of sorbitol in said liquid pharmaceutical composition is sufficient for the osmolality of said liquid pharmaceutical composition to be from about 220 mOsmol/kg to about 350 mOsmol/kg. 

 26. The liquid pharmaceutical composition of claim 24, wherein the concentration of sorbitol in said liquid pharmaceutical composition is sufficient for the osmolality of said liquid pharmaceutical composition to be from about 250 mOsmol/kg to about 320 mOsmol/kg. 

 27. The liquid pharmaceutical composition of claim 25, wherein the concentration of sorbitol in said liquid pharmaceutical composition is sufficient for the osmolality of said liquid pharmaceutical composition to be from about 250 mOsmol/kg to about 320 mOsmol/kg. 

 28. The liquid pharmaceutical composition of claim 2, wherein said liquid pharmaceutical composition comprises sucralose at a concentration of about 0.15% (w/v).